Nazione: Israele
Lingua: inglese
Fonte: Ministry of Health
CLINDAMYCIN HYDROCHLORIDE
PFIZER PFE PHARMACEUTICALS ISRAEL LTD
J01FF01
CAPSULES
CLINDAMYCIN HYDROCHLORIDE 150 MG
PER OS
Required
FAREVA AMBOISE, FRANCE
CLINDAMYCIN
CLINDAMYCIN
Treatment of infections caused by susceptible strains of anaerobic microorganisms.
2021-05-31
Dalacin C capsules PIL CC 121023 2023-0088338 1 PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS (PREPARATIONS) - 1986 This medicine is dispensed with a doctor’s prescription only DALACIN ® C CAPSULES 150 MG DALACIN ® C CAPSULES 300 MG CAPSULES EACH CAPSULE CONTAINS: Clindamycin hydrochloride 150 mg, 300 mg Inactive ingredients and allergens: See section 2 under "Important information about some of this medicine’s ingredients" and section 6 “Further information”. READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THIS MEDICINE. This leaflet contains concise information about this medicine. If you have any further questions, consult your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if it seems to you that their medical condition is similar to yours. 1. WHAT IS THIS MEDICINE INTENDED FOR? To treat infections caused by bacteria susceptible to clindamycin. THERAPEUTIC GROUP: Antibiotics from the lincosamide group. 2. BEFORE USING THIS MEDICINE DO NOT USE THIS MEDICINE IF: you are sensitive (allergic) to clindamycin, lincomycin or any of the other ingredients contained in the medicine (see section 6). SPECIAL WARNINGS REGARDING USE OF THE MEDICINE BEFORE TREATMENT WITH DALACIN C CAPSULES, TELL YOUR DOCTOR IF: you are suffering from diarrhea or generally suffer from diarrhea when you take antibiotics, or if you have ever suffered from gastric or intestinal problems. you are suffering, or have suffered in the past, from impaired function of the liver or kidneys. you are suffering from atopy (eczema, allergic rhinitis, asthma). ADDITIONAL WARNINGS REGARDING USE OF THE MEDICINE: The use of the medicine, similarly to other antibiotics, may cause diarrhea due to Clostridium difficile infection (CDAD). Tell the doctor immediately if you develop severe or prolonged diarrhea during or after use of this medicine. Prolonged use may also increase the risk of developing other infections not responding to treatment with Leggi il documento completo
Dalacin C Capsules LPD CC 121023 2023-0088338 1 DALACIN ® C CAPSULES 150 MG DALACIN ® C CAPSULES 300MG NAME OF THE MEDICINAL PRODUCT Dalacin® C Capsules 150 mg Dalacin® C Capsules 300 mg QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains clindamycin hydrochloride equivalent to 150mg or 300mg of clindamycin. Each capsule contains lactose. For the full list of excipients, see section Description (8) in this leaflet. PHARMACEUTICAL FORM Capsules.To reduce the development of drug-resistant bacteria and maintain the effectiveness of Dalacin C Capsules and other antibacterial drugs, Dalacin C Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. WARNING _Clostridioides difficile_ associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Dalacin C Capsules and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of _C. difficle._ Because Dalacin C Capsules therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. _C. difficile_ produces toxins A and B, which contribute to the development of CDAD. Hypertoxin producing strains of _C. difficile_ cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against _C_. _difficile_ may need to be discontinued. Leggi il documento completo